Jon Alexander L. A.
- Country
- Denmark
- Department
- Department of Oncology
Research Overview
- Phase 3 Randomized Open‑Label Study of ZL‑1310 versus Investigator‑Chosen Topotecan in Relapsed Small Cell Lung Cancer
- Phase 3 Randomized Trial of Pembrolizumab Versus Placebo in Stage IB-IIIA NSCLC Post-Resection and Adjuvant Therapy
- Efficacy and Safety of GDC-6036 Versus Sotorasib or Adagrasib in KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer
Data & Insights
Has run more than one trial at 64 of 232 partner sites.
Specializations
Lung Cancer Research
The investigator specializes in studying advanced treatments for non-small cell lung cancer (NSCLC), with particular emphasis on cases involving KRAS G12C mutations.
- Advanced Stage Lung Cancer
- Metastatic NSCLC
- KRAS-Mutated Cancers
A key focus area includes evaluating novel therapeutic approaches for patients with advanced lung cancer who have undergone previous treatments.
Precision Oncology
The investigator focuses on targeted therapy development and assessment, particularly in the field of KRAS inhibition for specific genetic mutations in lung cancer.
- Molecular Targeting
- Genetic Mutation Analysis
- Personalized Treatment Approaches
Research activities center on comparing the effectiveness of different targeted therapies in treating specific genetic variants of lung cancer.
Treatment Innovation
The investigator evaluates novel therapeutic agents for treating advanced lung cancer, with specific interest in comparative effectiveness research of new treatment options.
- Drug Efficacy Assessment
- Treatment Resistance
- Clinical Outcomes
Clinical research focuses on determining survival outcomes and safety profiles of emerging cancer treatments.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.